Here are the 10-K annual reports from Viatris Inc. (VTRS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VTRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTRS filings page.
Viatris Inc. filed its annual report outlining a global generics and brands business that generated $14.30 billion in 2025 total revenues while reshaping its portfolio through multiple divestitures and an expanding pipeline of complex and innovative drugs.
The company highlighted five positive Phase 3 data readouts, new launches such as iron sucrose injection in the U.S., and geographic expansion for Inpefa and other products. In 2025 Viatris returned more than $1 billion to shareholders, including about $500 million of share repurchases and $561 million in dividends.
An enterprise-wide strategic review led to a restructuring program with an expected global workforce reduction of up to 10%, projected pre-tax charges of $700–$850 million and targeted annual savings of $600–$700 million once fully implemented. The filing also describes remediation of an FDA warning letter for the Indore, India site and a temporary production halt following a fire at the Nashik, India facility, alongside extensive risk factor disclosures on pricing pressure, regulation, globalization and execution of its strategic plan.